LivaNova PLC
Financials
Valuation Metrics
LivaNova PLC's Market Cap is $4.53B. At end of 2025 it was $3.35B. Ranked #1467 of 3,112 in US market (top 47%), #509 of 1,445 on NASDAQ (top 35%), #85 of 206 in Health Care Equipment & Services (top 41%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $4.53B | US#1,467/3,112 Sec#85/206 |
| Revenue | $1.43B | US#1,694/3,112 Sec#104/206 |
| Net Income | $107M | US#1,580/3,112 Sec#78/206 |
| Total Assets | $2.52B | US#1,917/3,112 Sec#94/206 |
| Net Assets | $1.21B | US#1,639/3,112 Sec#87/206 |
| Employees | 3,300 | US#969/3,112 Sec#79/206 |
| Value | ||
| P/E | 42.28x | US#1,741/3,112 Sec#83/206 |
| P/B | 3.74x | US#1,917/3,112 Sec#116/206 |
| P/S | 3.16x | US#1,823/3,112 Sec#125/206 |
| EV/EBITDA | 20.05x | US#1,853/3,112 Sec#83/206 |
| FCF Yield | 3.56% | US#1,625/3,112 Sec#92/206 |
| Profitability | ||
| ROE | 8.85% | US#1,500/3,112 Sec#71/206 |
| ROA | 4.26% | US#1,139/3,112 Sec#71/206 |
| Op. Margin | 14.16% | US#1,287/3,112 Sec#50/206 |
| Revenue Growth | 14.33% | US#1,000/3,112 Sec#67/206 |
| Earnings Growth | -483.50% | US#2,325/3,112 Sec#123/206 |
| Financial Health | ||
| Debt Ratio | 107.74% | US#1,158/3,112 Sec#114/206 |
| Total Debt | $335M | US#1,996/3,112 Sec#105/206 |
| FCF | $161M | US#1,457/3,112 Sec#87/206 |
| Cash | $540M | US#1,030/3,112 Sec#58/206 |
| Current Ratio | 1.33x | US#1,843/3,112 Sec#166/206 |
| Net Debt/EBITDA | -0.95x | US#317/3,112 Sec#20/206 |
| Performance | ||
| 1Y Return | 100.49% | US#346/3,112 Sec#31/206 |
| 1M Return | -1.39% | US#1,838/3,112 Sec#124/206 |
| From 52W High | -3.30% | US#370/3,112 Sec#24/206 |
| 1Y MDD | -18.89% | US#603/3,112 Sec#10/206 |
| Trading | ||
| Volume | 551,881 shares | US#1,992/3,112 Sec#146/206 |
| Trading Value | $45M | US#1,437/3,112 Sec#106/206 |
| Per Share | ||
| EPS | $-4.45 | US—/3,112 Sec—/206 |
| BPS | $22.02 | US#1,112/3,112 Sec#65/206 |
Company Info
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.